Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma

Journal of Clinical Pathology

Volumn 49, Issue 4, 1996, Pages 295-299

  Ryder, S D ^a   Rizzi, P M ^a   Volkmann, M ^c   Metivier, E ^a   Pereira, L M M B ^a   Galle, P R ^c   Naoumov, N V ^a,d   Zentgraf, H ^b   Williams, R ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

anti p53; ELISA; Hepatocellular carcinoma; p53

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; PROTEIN P53; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

EID: 0029881701     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.4.295     Document Type: Article

References (19)

1. Oka H, Kurioka N, Kim K, Kanno T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12:680-7.
2. Wesic HT, Kirkpatric A. Alpha-fetoprotein and its relevance to human disease. Gastroenterology 1984;86:1404-9.
3. Colombo M, de Franchis R, Del-Ninno E, Sangiovanni A, De Faxio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80.
4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
5. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NY, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature 1991;350:427-8.
6. Volkmann M, Hofmann WJ, Muller M, Rath U, Otto G, Zentgraf H, et al. p53 over-expression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994;9:195-204.
7. Stephen CW, Lane DP. Mutant conformation of p53: precise epitope mapping using a filamentous phage epitope library. J Mol Biol 1992;225:577-83.
8. Volkmann M, Muller M, Hofmann WJ, Meyer M, Hagelstein J, Rath U, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of alpha-fetoprotein status. Hepatology 1993;18:559-65.
9. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1992;30:403-8.
10. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992; 231:3674-8.
11. Buchman VL, Chumakov PM, Ninkina N, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988;70: 245-52.
12. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent on p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-42.
13. Crawford LV, Pim DC, Lamb P. The cellular protein p53 in human tumours. Mol Biol Med 1984;2:261-72.
14. Labreque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
15. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52:4168-74.
16. Schlicholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52: 6380-4.
17. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, et al. p53 mutations in human lymphoid malignancies - associations with Burkitt lymphoma and chronic lymphocytic leukaemia. Proc Natl Acad Sci USA 1991;88:5413-17.
18. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsp70-p53 complex with an altered half life. Mol Cell Biol 1988;8: 531-9.
19. Dong X, Hamilton KJ, Satoh M, Wang J, Reeves WH. Initiation of auto-immunity to the p53 tumour suppressor protein by complexes of p53 and SV 40 large T antigen. J Exp Med 1994;179:1243-52.